Program Description

Triple-negative breast cancer (TNBC) remains a cancer of significant unmet need, with limited treatment options beyond systemic chemotherapy. Recent advancements in the development of novel targeted therapies incorporating actionable biomarkers have paved the way for personalizing treatment for patients with early to advanced TNBC. Currently, combinations of immune checkpoint inhibitors (ICI) and platinum-containing chemotherapy are the standard of care for advanced disease, but with the release of new clinical trial data, the treatment landscape continues to evolve, offering promise to these patients. Therapeutic strategies utilizing antibody-drug conjugates (ADCs), including those targeting TROP2, ICI combinations, and PARP inhibitors, can provide clinical benefit to patients with TNBC, with sequencing strategies also being explored. It is essential for clinicians who incorporate these tailored treatment approaches to navigate the practical challenges of treating the disease and managing adverse events while optimizing patient outcomes.


In this Medical Crossfire® program, expert faculty will discuss the latest evidence surrounding the role of novel and emerging combination therapies and sequencing strategies for the treatment of TNBC. Panel-style discussion of emerging therapies, optimal therapeutic selection and sequencing approaches across lines of therapy, and appropriate adverse event management, will help to provide insight into best practices for integrating these data into clinical practice.

Speakers

Panelist: Marleen Kok MD, PhD
The Netherlands Cancer Institute
Group Leader, Breast Cancer Immunotherapy Group
Netherlands, Amsterdam

Panelist: Alison K. Conlin MD
Providence Cancer Institute
Medical Oncologist
Portland, OR

Panelist: Heather McArthur MD, MPH
UT Southwestern Medical Center
Clinical Director, Breast Cancer Program
Dallas, TX

Program Chair: Hope S. Rugo, MD, FASCO
City of Hope Comprehensive Cancer Center
Director, Women’s Cancers Program
Duarte, CA